Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Developing treatments for fatty liver disease has proved challenging, and there are currently no approved medications.
Abnormal body fat distribution includes visceral fat and a hard belly.
Abnormal body fat distribution is still a concern for many people living with HIV.
The injectable hormone helps reduce inflammation and fibrosis associated with NAFLD in this population.
Understanding lipodystrophy among people living with HIV, including visceral fat and hard belly.
Egrifta SV is easier to prepare and does not require refrigeration
The injectable hormone was approved to treat excess abdominal fat in those with antiretroviral-associated lipodystrophy.
I know it won’t solve all my lipodystrophy challenges, but I’m feeling desperate to improve my body. Do you relate?
Taking Egrifta and getting CoolSculpt: Is this a midlife crisis or a healthy reality?
There are various options for treating the symptoms of lipodystrophy, both in terms of fat buildup and fat loss.
Many people living with HIV may find they gain a strange type of weight.
The drug Egrifta (tesamorelin), developed as a treatment for excess abdominal fat in people with HIV, may have an additional benefit of promot...
The injectable drug Egrifta (tesamorelin) led to modest drops in abdominal and liver fat levels in a preliminary study of people with HIV.
Older medications are more likely to cause this change in the body.
Theratechnologies has announced a major shortage of its drug Egrifta (tesamorelin, for injection), which reduces HIV-related excess belly fat.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.